SEARCH

SEARCH BY CITATION

References

  • 1
    Bilbao JI, Quiroga J, Herrero JI, Benito A. Transjugular intrahepatic portosystemic shunt (TIPS): current status and future possibilities. Cardiovasc Intervent Radiol 2002; 25: 251269.
  • 2
    Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 11921197.
  • 3
    Rössle M, Deibert P, Haag K, Ochs A, Olschewski M, Siegerstetter V, Hauenstein K-H, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349: 10431049.
  • 4
    Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, Berger E, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165171.
  • 5
    Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep 2000; 2: 6171.
  • 6
    Luca A, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999; 212: 411421.
  • 7
    Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30: 612622.
  • 8
    Rossle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998; 18: 7389.
  • 9
    Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 18391847.
  • 10
    Rössle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 17011707.
  • 11
    Sanyal AJ, Genning C., Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634641.
  • 12
    Cejna M, Peck-Radosavljevic M, Thurnher S, Schoder M, Rand T, Angermayr B, Lammer J. ePTFE-covered stent-grafts for revision of obstructed transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2002; 25: 365372.
  • 13
    Cejna M, Peck-Radosavljevic M, Thurnher SA, Hittmair K, Schoder M, Lammer J. Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. Radiology 2001; 221: 437446.
  • 14
    Haskal ZJ. Improved patency of transjugular intrahepatic portosystemic shunts in humans: creation and revision with PTFE stent-grafts. Radiology 1999; 213: 759766.
  • 15
    Otal P, Smayra T, Bureau C., Peron JM, Chabbert V, Chemla P, Joffre F, et al. Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. AJR Am J Roentgenol 2002; 178: 141147.
  • 16
    Cejna M, Peck-Radosavljevic M, Schoder M, Thurnher S, Ba-Ssalamah A, Angermayr B, Kaserer K, et al. Repeat interventions for maintenance of transjugular intrahepatic portosystemic shunt function in patients with Budd-Chiari syndrome. J Vasc Interv Radiol 2002; 13: 193199.
  • 17
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164176.
  • 18
    Cejna M, Thurnher S, Pidlich J, Kaserer K, Schoder M, Lammer J. Primary implantation of polyester-covered stent-grafts for transjugular intrahepatic portosystemic stent shunts (TIPSS): A pilot study. Cardiovasc Intervent Radiol 1999; 22: 305310.
  • 19
    LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA, Roberts JP, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187: 413420.
  • 20
    Angermayr B, Cejna M, Schoder M, Wrba F, Valent P, Gangl A, Peck-Radosavljevic M. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood 2002; 99: 42464247.
  • 21
    World Medical Organization. Declaration of Helsinki. Br Med J 1996; 313: 14481449.
  • 22
    Infante-Rivard C., Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660664.
  • 23
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864871.
  • 24
    Sanyal AJ, Freedman AM, Luketic VA, Purdum PP 3rd, Shiffman ML, DeMeo J, Cole PE, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889898.
  • 25
    Bureau C., Otal P, Chabbert V, Peron JM, Rousseau H, Vinel JP. Segmental liver ischemia after TIPS procedure using a new PTFE-covered stent. Hepatology 2002; 36: 1554.
  • 26
    Rossle M. Prevention of rebleeding from oesophageal-gastric varices. Eur J Gastroenterol Hepatol 2001; 13: 343348.
  • 27
    Cabrera J, Maynar M, Granados R, Gorriz E, Reyes R, Pulido-Duque JM, Rodriguez SanRoman JL, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110: 832839.
  • 28
    Escorsell A, Banares R, Garcia-Pagan JC., Gilabert R, Moitinho E, Piqueras B, Bru C., et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35: 385392.
  • 29
    Garcia-Villarreal L, Martinez-Lagares F, Sierra A, Guevara C., Marrero JM, Jimenez E, Monescillo A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29: 2732.
  • 30
    Merli M, Salerno F, Riggio O, de Franchis R, Fiaccadori F, Meddi P, Primignani M, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998; 27: 4853.
  • 31
    Haskal ZJ, Davis A, McAllister A, Furth EE. PTFE-encapsulated endovascular stent-graft for transjugular intrahepatic portosystemic shunts: experimental evaluation. Radiology 1997; 205: 682688.
  • 32
    Saxon RR, Timmermans HA, Uchida BT, Petersen BD, Benner KG, Rabkin J, Keller FS. Stent-grafts for revision of TIPS stenoses and occlusions: a clinical pilot study. J Vasc Interv Radiol 1997; 8: 539548.
  • 33
    Sze DY, Vestring T, Liddell RP, Kato N, Semba CP, Razavi MK, Kee ST, et al. Recurrent TIPS failure associated with biliary fistulae: treatment with PTFE-covered stents. Cardiovasc Intervent Radiol 1999; 22: 298304.
  • 34
    Haskal ZJ, Pentecost MJ, Soulen MC., Shlansky-Goldberg RD, Baum RA, Cope C. Transjugular intrahepatic portosystemic shunt stenosis and revision: early and midterm results. AJR Am J Roentgenol 1994; 163: 439444.
  • 35
    Latimer J, Bawa SM, Rees CJ, Hudson M, Rose JD. Patency and reintervention rates during routine TIPSS surveillance. Cardiovasc Intervent Radiol 1998; 21: 234239.
  • 36
    Stanley AJ, Jalan R, Forrest EH, Redhead DN, Hayes PC. Long-term follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients. Gut 1996; 39: 479485.
  • 37
    de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001; 5: 645663.
  • 38
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726748.
  • 39
    Kramer L, Horl WH. Hepatorenal syndrome. Semin Nephrol 2002; 22: 290301.
  • 40
    Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879885.
  • 41
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464470.
  • 42
    D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468475.
  • 43
    Pagliaro L, D'Amico G, Pasta L, Portal hypertension in cirrhosis: natural history. In: BoschJ, GroszmannRJ, eds. Portal Hypertension: Pathophysiology and Treatment. Oxford; Blackwell Scientific Publications: 1994; 7292.
  • 44
    Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, Fusini M, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88: 514519.
  • 45
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC., Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902908.
  • 46
    Bosch J. Medical treatment of portal hypertension. Digestion 1998; 59: 547555.
  • 47
    Feu F, Garcia-Pagan JC., Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 10561059.